169 related articles for article (PubMed ID: 37990919)
1. Rectal delivery of
Fan Y; Wang X; Yan G; Gao H; Yang M
J Mater Chem B; 2023 Dec; 11(47):11228-11234. PubMed ID: 37990919
[TBL] [Abstract][Full Text] [Related]
2. Oral infliximab nanomedicines for targeted treatment of inflammatory bowel diseases.
Mohan LJ; Daly JS; Ryan BM; Ramtoola Z
Eur J Pharm Sci; 2023 Apr; 183():106379. PubMed ID: 36646154
[TBL] [Abstract][Full Text] [Related]
3. Immuno-PET Imaging of TNF-α in Colitis Using
Yan G; Wang X; Fan Y; Lin J; Yan J; Wang L; Pan D; Xu Y; Yang M
Mol Pharm; 2022 Oct; 19(10):3632-3639. PubMed ID: 36039398
[TBL] [Abstract][Full Text] [Related]
4. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
7. The treatment of inflammatory bowel disease with monoclonal antibodies in Asia.
Chen Y; Zhang G; Yang Y; Zhang S; Jiang H; Tian K; Arenbaoligao ; Chen D
Biomed Pharmacother; 2023 Jan; 157():114081. PubMed ID: 36481399
[TBL] [Abstract][Full Text] [Related]
8. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
[TBL] [Abstract][Full Text] [Related]
9. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
[TBL] [Abstract][Full Text] [Related]
10. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
Kujundzić M
Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
[TBL] [Abstract][Full Text] [Related]
11. Oral delivery of infliximab using nano-in-microparticles for the treatment of inflammatory bowel disease.
Li X; Yu M; Zhu Z; Lu C; Jin M; Rao Y; Zhao Q; Lu X; Yu C
Carbohydr Polym; 2021 Dec; 273():118556. PubMed ID: 34560967
[TBL] [Abstract][Full Text] [Related]
12. An update on biosimilar drugs for inflammatory bowel disease.
Schreiber S
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
[TBL] [Abstract][Full Text] [Related]
13. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions.
Eder P; Zielińska A; Karczewski J; Dobrowolska A; Słomski R; Souto EB
J Nanobiotechnology; 2021 Oct; 19(1):346. PubMed ID: 34715852
[TBL] [Abstract][Full Text] [Related]
14. [Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets].
Flamant M; Bourreille A
Rev Med Interne; 2007 Dec; 28(12):852-61. PubMed ID: 17628232
[TBL] [Abstract][Full Text] [Related]
15. Anti-Tumor Necrosis Factor Therapy and Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease.
Peter I; Dubinsky M; Bressman S; Park A; Lu C; Chen N; Wang A
JAMA Neurol; 2018 Aug; 75(8):939-946. PubMed ID: 29710331
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment.
Bergamaschi G; Di Sabatino A; Albertini R; Ardizzone S; Biancheri P; Bonetti E; Cassinotti A; Cazzola P; Markopoulos K; Massari A; Rosti V; Porro GB; Corazza GR
Haematologica; 2010 Feb; 95(2):199-205. PubMed ID: 19815838
[TBL] [Abstract][Full Text] [Related]
17. Biological therapy of inflammatory bowel disease.
Owczarek D; Cibor D; Szczepanek M; Mach T
Pol Arch Med Wewn; 2009; 119(1-2):84-8. PubMed ID: 19341184
[TBL] [Abstract][Full Text] [Related]
18. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update.
Vulliemoz M; Brand S; Juillerat P; Mottet C; Ben-Horin S; Michetti P;
Digestion; 2020; 101 Suppl 1():16-26. PubMed ID: 32739923
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety.
Ngo B; Farrell CP; Barr M; Wolov K; Bailey R; Mullin JM; Thornton JJ
Curr Mol Pharmacol; 2010 Nov; 3(3):145-52. PubMed ID: 20799925
[TBL] [Abstract][Full Text] [Related]
20. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
